Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Eslicarbazepine Acetate in Moderate Hepatic Impairment
NCT02281526Phase 1Completed
- Sponsor
- BIAL
- Start
- May 2005
- Primary completion
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of eslicarbazepine acetate in epilepsy (2 arms), sponsored by BIAL. Primary endpoint: Area Under the Plasma Concentration Versus Time Curve, AUC(0-tlast) at 24 hours. Started May 2005; status: completed.
02
Drugs
eslicarbazepine acetate
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT02281526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02281526.